Sarabjit Kaur Nangra of Angel Broking is neutral on Cipla as of now because the price has run up ahead of fundamentals.

Cipla Q4 profit seen up 29% at Rs 335.8 cr: Poll

Cipla's fourth quarter profit is expected to increase 29 percent year-on-year to Rs 335.8 crore and revenue to jump 16.4 percent to Rs 2,827.2 crore, according to a CNBC-TV18 poll.

Mixed Q3 nos for pharma so far: Here's what you should buy

Hitesh Mahida is bullish on Cipla, Glenmark and Dr Reddy‘s Laboratories from the large cap pharma space and suggests caution on Lupin for now.

Cipla Q3 profit may climb 27% to Rs 361 cr: CNBC-TV18 Poll

Cipla's third quarter profit may jump 27 percent year-on-year to Rs 360.6 crore, according to the average of estimates of analysts polled by CNBC-TV18.

Cipla Q2 disappoints; net profit down 16.6%

Disappointing set of numbers from Cipla in the September quarter. Cipla reported a poor operating performance on back of muted sales growth and a sharp decline in exports.

US core business continues to be a drag for Ranbaxy: CIMB

Prakash Agarwal, Equity Analyst, CIMB has a hold rating on Ranbaxy with target price of Rs 630/share.

Religare downgrades Cipla on cost overruns

Arvind Bothra of Religare Capital Markets expects Cipla's full margins to be 20-21 percent. But adds if scale up in R&D continues at this pace and approvals from the US do not come through, margins could dip further.

FY15 capex Rs 400 cr, aiming for 20% EBITDA growth: Cipla

Rajesh Garg, global chief financial officer, Cipla, told CNBC-TV18 that operating profits were impacted in the absence of anti-depressant Escitalopram sales in the US, and higher sales of anti-retroviral (ARV) drugs, where profit margins are low.

Cipla Q3 PAT may rise 6.1% to Rs 360 cr: CNBC-TV18 poll

Analysts feel profit after tax of Cipla may come in as low as Rs 300 crore during the quarter due to margin pressure.

Pharma companies revenues to rise 12% in Q3: Anand Rathi

Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

H1 inline; Cipla Medpro fully integrated: Cipla MD

Cipla MD & Global CEO Subhanu Saxena says he had signaled that the first 12-18 months in its roadmap was investing in the business for the future - particularly on people and also the pipeline to get in a position where it'll have sustainable platform for growth for the decade and beyond.

Cipla Q2 PAT may dip 27.3% at Rs 363.3 cr: ICICIdirect

Revenues of Cipla are expected to decrease by 0.6 percent Q-o-Q (up 11.7 percent Y-o-Y) to Rs 2448.9 crore.

Experts laud Cipla Q1 results; doubt Sun Pharma guidance

Vivek Kumar Pharma Analyst SBI Cap Securities and Praful Bohra Senior Research Analyst Pharma, Nirmal Bang Institutional Equities share their views on the results of both the companies.

Cipla Q1 PAT may dip 15% at Rs 340 cr: Nirmal Bang

Nirmal Bang expects Cipla to report a 26.9 percent growth quarter-on-quarter (fall of 15.3 percent year-on-year) in net profit at Rs 339.6 crore.

Cipla Q1 net seen down 18% at Rs 328 cr: P Lilladher

Prabhudas Lilladher expects Cipla to report a 22.7 percent growth quarter-on-quarter (fall of 18.1 percent year-on-year) in net profit at Rs 328.2 crore.

Cipla Q1 PAT seen up 12.2% at Rs 343 cr: Motilal Oswal

Motilal Oswal expects Cipla to report a 28.2 percent growth quarter-on-quarter (rise of 12.2 percent year-on-year) in net profit at Rs 342.9 crore.

Cipla Q1: Analysts see 17% drop in profit at Rs 332 cr

Cipla's earning before interest, tax, depreciation & amortisation (EBITDA) is seen going down by 9 percent Y-o-Y to Rs 491 crore due to higher research & development cost and operating profit margin may drop 450 bps Y-o-Y to 23 percent for the quarter ended June 2013.

Cipla eyes strong intl growth; emerging mkts in focus

Cipla aims to focus more on international business and will strengthen its presense in US, Europe. The company is also closely eyeing emerging markets

Pharma cos likely to post 21% EBITDA growth in Q4: MOST

Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

Cipla Q3: Analysts expect Q3 profit to grow 38% at Rs 372cr

Healthcare firm Cipla is set to announce its results for the third quarter of financial year 2012-13 on Wednesday. Analysts on an average expect the company to report good numbers year-on-year due to overall operational improvement.

See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.

Cipla Q2 net sales rises 33% to Rs 2,146 cr

Pharmaceutical firm Cipla's net sales increased 33 percent YoY to Rs 2,146 crore in the July-September quarter of 2012, out of which 44 percent contribution came from local business and 56 percent from international, Hamied says.

Aim to see turnover of USD 5 bn by 2020: Cipla Chairman

Cipla reported a better-than-expected second quarter earnings. In an interview to CNBC-TV18, Chairman of the company YK Hamied said that the pharma major is expecting to achieve a turnover of USD 5 billion by the year 2020.

Cipla Q2 revenues seen up 26% to Rs 2,030 cr

Drug producer Cipla's revenues are seen going up by 26 percent to Rs 2,030 crore from Rs 1,615 crore during the same period.

Cipla Q2 PAT seen up 37.5% to Rs 361 cr

Drug producer Cipla's profit after tax is expected to go up by 37.5 percent year-on-year to Rs 361 crore in the quarter ended September 2012.